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Introduction {#sec005}
============

Orthopedic trauma (OT) patients are routinely afflicted by pain and it is considered the most common and debilitating symptom reported among this population \[[@pone.0226452.ref001], [@pone.0226452.ref002]\]. Optimal pain control is an OT care priority as pain interferes with trauma recovery and affects outcome \[[@pone.0226452.ref003], [@pone.0226452.ref004]\].

A growing body of research is currently focused on developing alternative pain management techniques to tackle the alarming drawbacks associated with current standards of care. Among these alternatives, transcranial magnetic stimulation (TMS) has gained attention in recent years for its dual role: 1) its ability to objectively assess pain mechanisms; and 2) its potential applicability in pain management. In chronic pain studies, the primary motor cortex (M1) commonly serves as the targeted brain region due to its connections with the nociceptive system and the known effect of pain on motor function \[[@pone.0226452.ref005], [@pone.0226452.ref006]\]. Despite some variability across TMS studies, there is extensive evidence of an altered balance between inhibitory and facilitatory circuits of M1 in various chronic pain conditions (i.e. fibromyalgia, neuropathic pain, complex regional pain syndrome, phantom limb pain, chronic orofacial pain) \[[@pone.0226452.ref007], [@pone.0226452.ref008]\]. These results highlight maladaptive plasticity within the motor system. M1-cortical excitability alterations have been associated with the severity of the clinical symptoms such as pain intensity, hyperalgesia, and allodynia \[[@pone.0226452.ref009], [@pone.0226452.ref010]\], pointing to the value of TMS as an objective tool that reflects functional alterations. Moreover, cortical excitability restoration through repetitive TMS (rTMS), a technique known to induce lasting modulation effects on brain activity through a multiple day session paradigm, has shown some efficacy in reducing the magnitude of pain, even in refractory chronic pain patients \[[@pone.0226452.ref011]--[@pone.0226452.ref016]\]. Overall, these results support the role of cortical excitability on pain intensity in chronic pain patients and the potential clinical utility of TMS in pain management among this population.

On the other hand, acute pain initiated by an OT, such as following a fracture, has received little to no attention, despite being highly prevalent. With 15% to 20% of all physician visits intended to address pain-related issues \[[@pone.0226452.ref017], [@pone.0226452.ref018]\], management of acute pain following OT still remains medically challenging \[[@pone.0226452.ref019]--[@pone.0226452.ref022]\]. Knowing that acute and chronic pain belong to the same continuum and that there is clear evidence of success in the use of rTMS in treating chronic pain, this technique could serve as a potential treatment tool in the early phase of fracture pain by tackling key elements of pain chronification. First, however, a better understanding of the involvement of M1-cortical excitability in acute pain is necessary.

From a physiological point of view, it remains unclear whether motor cortical excitability impairments are expected in a context of acute pain following an OT. On one hand, neuroimaging studies suggest that possible disturbances within M1 only arise once chronic pain has developed, with acute and chronic pain exhibiting distinct and non-overlapping brain activation patterns \[[@pone.0226452.ref023]--[@pone.0226452.ref027]\]. On the other hand, there is evidence supporting alterations of M1-cortical excitability during acute pain states. Indeed, Voscopoulos and Lema highlight early neuroplasticity involvement of GABA inhibitory interneurons following a peripheral insult, which may contribute to later transition to chronic pain \[[@pone.0226452.ref028]\]. In parallel, Pelletier and colleagues \[[@pone.0226452.ref029]\] suggested that pain intensity may act as the driving factor leading to M1-cortical excitability alterations rather than the state of chronic pain itself. This assumption was made by authors after obtaining similar M1 deficiency patterns across chronic pain conditions of various origins. Other TMS studies also showed that pain of moderate to severe intensity (score ≥4 on numerical rating scale (NRS)) leads to greater motor cortex impairments \[[@pone.0226452.ref010]\]. The relationship between pain intensity in the acute state and its impact on cortical excitability parameters appears a relevant target of investigation.

So far, very few studies have looked into the association between acute pain and M1-cortical excitability. These studies have mainly focused on experimental pain models in healthy subjects. More specifically, acute experimental pain of low-to-moderate intensity induces a generalized state of M1 inhibition, reflecting changes in both cortical and spinal motoneuronal excitability in healthy participants \[[@pone.0226452.ref030]--[@pone.0226452.ref035]\]. Findings suggest that acute experimental pain can modify cortical excitability of M1, but the result patterns obtained are different from chronic pain states. In parallel, rTMS studies have been shown effective in both alleviating acute experimental pain and modulating alterations in M1-cortical excitability \[[@pone.0226452.ref036], [@pone.0226452.ref037]\]. Taken together, these findings show that M1 alterations can occur in the context of acute pain and that rTMS over M1 can successfully modulate nociceptive afferent information and restore M1 alterations, even for transient pain sensation in healthy controls. However, due to the subjective nature of pain sensation along with intrinsic differences in pain characteristics across conditions and individuals, translation between experimental pain model and clinical pain following an OT is limited. Therefore, if we are to consider the potential clinical utility of rTMS in alleviating acute pain, studies need to be conducted in a clinical population.

This study therefore aims to assess acute M1-cortical excitability functioning through well-established TMS paradigms according to pain intensity in patients who are in the acute pain phase following an isolated upper limb fracture (IULF). We hypothesize that M1-cortical excitability alterations will be found in patients with higher levels of pain compared to healthy controls and to IULF patients with mild pain.

Materials and methods {#sec006}
=====================

This work was approved by the Hôpital du Sacré-Coeur de Montréal\' Ethics Committee (Approval number: 2017--1328). A written consent was obtained by all participating subjects prior to the start of the study. A financial compensation was given to all subjects for their participation.

Participants {#sec007}
------------

Our sample included 1) patients who have suffered from an isolated upper limb fracture (IULF) and 2) healthy controls. Patients with an IULF were initially recruited from various orthopedic clinics affiliated to a Level 1 Trauma Hospital. To be included in the study, patients had to be aged between 18 and 60 years old and have sustained an IULF (one fractured bone from upper body extremities) within 14 days post-injury. Recruitment of IULF patients took place on the day of the first medical appointment at the orthopedic trauma clinic with the orthopedic surgeon. Testing was conducted within 24 hours post-medical consultation. All testing measures had to be completed prior to surgical procedures (if any) given the known impact of surgery on increased inflammatory response and pain perception \[[@pone.0226452.ref038]\]. Exclusion criteria consisted of a history of traumatic brain injuries, a diagnosis of and/or a treatment for a psychiatric condition in the last ten years, musculoskeletal deficits, neurological conditions (i.e. epilepsy), chronic conditions (cancer, uncontrolled diabetes, cardiovascular illness, high blood pressure), the use of central nervous system-active medication (hypnotics, antipsychotics, antidepressant, acetylcholinesterase inhibitor, anticonvulsant), history of alcohol and/or substance abuse, acute medical complications (concomitant traumatic brain injury, neurological damage, etc.), and being intoxicated at the time of the accident and/or at the emergency visit. Of note, IULF patients were not restrained from using analgesic medication (acetaminophen, ibuprofen, opioids, etc.) during testing to assure comfort and to avoid interfering with pain management.

The control group consisted of healthy right-handed adults recruited through various social media platforms. As per usual practice in conducting M1 TMS studies, only right-handed control participants were selected as stimulation over non-dominant M1 has been associated with accentuated within-subject variability \[[@pone.0226452.ref039], [@pone.0226452.ref040]\]. They self-reported to be free of all previously mentioned exclusion criteria.

Study participants were also screened for TMS tolerability and safety \[[@pone.0226452.ref041]\].

Assessment measures {#sec008}
-------------------

Total assessment procedures (including consent) were conducted over a single, 90-minute session. First, participants were invited to complete self-administered questionnaires to gather demographic information and clinical outcome measures (pain intensity and functional disability indices). More specifically, demographic data such as age, sex, and level of education were documented and used to ensure homogeneity between groups.

### Clinical outcome: Pain intensity and functional disability indices {#sec009}

To assess the perceived level of pain at the time of testing, the numerical rating scale (NRS), a routinely used standardized generic unidimensional clinical pain questionnaire, was administered \[[@pone.0226452.ref042], [@pone.0226452.ref043]\]. To complete the NRS, participants had to circle a number that best fit their current level of pain on the 11-point pain intensity scale, with numbers ranging from 0 ("no pain") to 10 ("worst possible pain"). In order to test the hypothesized impact of acute pain intensity on M1 cortical excitability, IULF patients were divided into two distinct groups according to NRS score: 1) IULF patients who self-reported moderate to severe pain intensity (NRS ≥4 out of 10); 2) IULF patients with mild pain intensity (NRS \<4). The cut-off pain intensity scores are based on previous pain studies \[[@pone.0226452.ref010], [@pone.0226452.ref044], [@pone.0226452.ref045]\].

The disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire was used as a tool to assess an individual's ability to perform common specific everyday activities relying on upper extremity limbs \[[@pone.0226452.ref046], [@pone.0226452.ref047]\]. This questionnaire consists of 30 items, including 6 that are symptom-related and 24 that are function-related, where patients were asked to rate the level of disability on each activity as experienced since their accident. Continuum of scores on this questionnaire varies between 0 (no disability) and 100 (extreme difficulty).

### Comprehensive assessment of M1 cortical excitability using TMS {#sec010}

To assess M1 cortical excitability, a TMS figure-of-eight stimulation coil (80mm wing diameter), attached to a Bistim^2^ Magstim transcranial magnetic stimulators (*Magstim Company*, Whitland, Dyfed, UK), was used. The TMS-coil was positioned flat on the scalp over M1 at a 45° angle from the mid-sagittal line, with its handle pointing backwards. In the IULF group, the TMS coil was positioned over M1 contralaterally to the injury, whereas in the control group, the TMS-coil was systematically positioned over the dominant left hemisphere. Motor evoked potentials (MEP) recordings from the abductor pollicis brevis (APB) was performed using three electrodes positioned over the belly of the target muscle (active electrode (+)), between the distal and proximal interphalangeal joints of the index (reference (-)), and on the forearm (ground). Optimal stimulation site was determined based on the coil position which evoked highest peak-to-peak MEP amplitudes from the target muscle. We used a 3D tracking system (Northern Digital Instruments, Waterloo, Canada) to ensure accurate and consistent TMS coil positioning on the targeted site.

Various well-established TMS protocols were conducted to investigate M1 excitatory and inhibitory mechanisms using single and paired-pulse paradigms. Single pulse magnetic stimulations were first used to establish the resting motor threshold (rMT), i.e. the minimal stimulation intensity needed to elicit a MEP of at least 0.05mV in five out of ten trials \[[@pone.0226452.ref048]\]. An interstimulus interval, varying from 8 to 10 seconds, was applied to control for possible residual effects of TMS stimulation on M1 activity \[[@pone.0226452.ref049]\]. The sequence of stimulation intensity was randomly generated by a computer. Short intra-cortical-inhibition (SICI) and facilitation (ICF) were measured via a classic paired-pulse paradigm \[[@pone.0226452.ref050], [@pone.0226452.ref051]\]. The latter protocol involves the application of two successive TMS pulses, the first pulse set at 80% of the rMT intensity (subthreshold; conditioning stimulus) and the second pulse set at 120% of the rMT (suprathreshold; test stimulus) separated by an interstimulus interval (ISI) of a predetermined duration \[[@pone.0226452.ref050]\]. To test for SICI, a measure attributed to GABA~A~ interneurons and receptors activity \[[@pone.0226452.ref052]\], one sequence of 10 paired-pulse stimulations was completed with an ISI set at 3ms. To test for ICF, one sequence of 10 stimulations was performed with ISI set at 12ms. Measure of ICF is thought to be mediated by excitatory glutamatergic interneurons and N-methyl-D-aspartate (NMDA) receptors \[[@pone.0226452.ref052]--[@pone.0226452.ref056]\]. Results of SICI and ICF are expressed as percentage ratios of MEP amplitudes. These ratios represent the mean MEP amplitude of paired TMS over the mean MEP amplitude of the test stimuli baseline measurement (10 single magnetic pulses set at 120% rMT). Therefore, high SICI values reflect a lack of intracortical inhibition, whereas a low value ICF corresponds to a lack of intracortical facilitation. Finally, we measured long-interval cortical inhibition (LICI) through paired-pulse TMS of identical suprathreshold intensity (i.e. 120% rMT) with an ISI of 100ms. The first pulse corresponded to the conditioning stimulus whereas the second pulse was the test stimulus. LICI is primarily known to be mediated by GABA~B~ receptors \[[@pone.0226452.ref057], [@pone.0226452.ref058]\]. To calculate LICI, we used the percentage ratio between the mean peak-to-peak MEP amplitude of the test stimulus response (TSR) and the mean peak-to-peak MEP amplitude of the conditioning stimulus response (CSR) expressed as: mean (TSR)/mean(CSR).

Statistics {#sec011}
----------

Statistical analyses were performed using IBM SPSS Statistics software version 25 (Armonk, NY, United States). The Shapiro-Wilks test was used to determine the normality of the data. Parametric and nonparametric tests were performed, where appropriate, with a α-level fixed at 0.05. Descriptive analyses were used to characterize and compare the three groups (1- IULF patients with NRS≥4; 2- IULF patients with NRS\<4; 3- healthy controls) in our study sample. Results from descriptive analyses are expressed as means, standard deviation (SD), and percentages. We used a Student's t-test or a Mann-Whitney U test to investigate group differences on TMS measures. An analysis of variance (ANOVA) or the Kruskal-Wallis test were also used where appropriate. Pearson and Spearman's correlation analysis were also computed to assess the relationship between functional disability outcomes and the other outcome measures of interest (pain intensity and TMS measures). We corrected for multiple comparisons using False Discovery Rate (FDR) where appropriate. Post-hoc analyses were conducted to control for the effect of within-group variability of stimulated hemispheres across IULF patients on TMS measures as it varied according to the injury location (left or right). Therefore, we elected to create subgroups as follow: IULF patients stimulated over the left hemisphere (IULF with left-M1) and IULF patients stimulated on the right hemisphere (IULF with right-M1). Lastly, a post-hoc linear regression analysis was computed to assess which independent variables between pain intensity (NRS score from 0--10) and the number of days between the accident and testing (independent variable) best predict significant changes in M1-cortical excitability (dependent variable) in IULF patients.

Results {#sec012}
=======

Demographic information {#sec013}
-----------------------

A total of 84 subjects took part in the current study, of which 56 had suffered an IULF (23 females; mean age: 39.41 years old) and 28 were healthy controls (17 females; mean age: 34.93). Two subgroups of IULF patients were formed according to pain intensity: Twenty-five IULF individuals met the criteria for moderate to severe pain (NRS ≥4), whereas 31 IULF subjects were classified as having mild pain (NRS \<4). Age (H = 3.89; p = 0.14) and sex (F~(81)~ = 3.76; p = 0.15) did not differ between groups, whereas the level of education (F~(81)~ = 3.95; p = 0.02) and the time elapsed between the accident and testing (*U* = 225.50; p = 0.01) were statistically different across groups. More specifically, IULF patients with NRS≥4 were tested on average 4.48 (SD = 3.50) days post-accident compared to 7.55 (SD = 4.45) days for IULF patients with NRS\<4. Spearman's correlational analyses revealed a strong association between pain intensity and the extent of functional disability as measured through the DASH questionnaire (r~s~ = 0.76; p\<0.001). Refer to Tables [1](#pone.0226452.t001){ref-type="table"}--[2](#pone.0226452.t002){ref-type="table"} for additional descriptive information regarding study sample and fracture distribution among IULF patients.

10.1371/journal.pone.0226452.t001

###### Descriptive characteristics of study cohort by group.

![](pone.0226452.t001){#pone.0226452.t001g}

                                                                                     IULF subgroup NRS ≥4   IULF subgroup NRS \<4   Healthy controls   Results of analysis   p-value
  ---------------------------------------------------------------------------------- ---------------------- ----------------------- ------------------ --------------------- -----------
  N ***(subjects)***                                                                 25                     31                      28                                       --
  Age ***(years \[SD\])***                                                           42.36 (13.83)          37.03 (12.02)           34.93 (11.95)      *H =* 3.89            0.14
  Sex ***(female \[%\])***                                                           12 (48%)               11 (35%)                17 (61%)           F = 3.76              0.15
  Education ***(years \[SD\])***                                                     13.44 (2.65)           14.74 (2.86)            15.54 (2.65)       F = 3.95              0.02\*
  Number of days between trauma and data collection/assessment ***(days \[SD\])***   4.48 (3.50)            7.55 (4.45)             --                 *U =* 225.50          0.01\*
  Side of the stimulated hemisphere ***(left \[%\])***                               10 (40%)               17 (55%)                --                 X^2^ = 1.22           0.30
  NRS Actual pain ***(SD)***                                                         5.64 (1.41)            1.26 (1.00)             0.14 (0.36)        *H =* 65.46           \<0.001\*
  DASH score ***(SD)***                                                              56.15 (16.56)          45.58 (17.43)           1.90 (3.04)        *H =* 56.55           \<0.001\*

10.1371/journal.pone.0226452.t002

###### Fracture distribution among IULF patients.

![](pone.0226452.t002){#pone.0226452.t002g}

  Type of fracture       N (subjects \[%\])
  ---------------------- --------------------
  \- **Radial head**     11(19.64)
  \- **Collarbone**      8 (14.29)
  \- **Humerus**         9 (16.07)
  \- **Distal radius**   21 (37.50)
  \- **Scaphoid**        4 (7.14)
  \- **Scapula**         1 (1.79)
  \- **Ulna**            2 (3.57)

Group differences on M1-cortical excitability measures in relation to pain threshold {#sec014}
------------------------------------------------------------------------------------

### Resting motor threshold (rMT) {#sec015}

Mann-Whitney U test revealed that IULF patients with NRS≥4 did not statistically differ from IULF patients with NRS\<4 (*U* = 324.50; p = 0.54) and healthy controls (*U* = 323.50; p = 0.82) on rMT. Similarly, IULF patients with NRS\<4 showed equivalent rMT measures as healthy controls (*U* = 365.00; p = 0.39). See [Fig 1A](#pone.0226452.g001){ref-type="fig"}.

![Groups differences on TMS measures.\
A. Between group comparison on rMT. B. Between group comparison on MEPs test stimulus intensity. C. Between group comparison on SICI. D. Between group comparison on ICF. E. Between group comparison on LICI.](pone.0226452.g001){#pone.0226452.g001}

### MEPs test stimulus intensity {#sec016}

MEPs of the test stimulus used to measure SICI and ICF were equivalent between groups. Indeed, IULF patients with NRS≥4 did not statistically differ from IULF patients with NRS\<4 (U = 336.00; p = 0.40) and healthy controls (U = 304.00; p = 0.41). Moreover, IULF patients with NRS\<4 and healthy controls were comparable (U = 431.00; p = 0.96). See [Fig 1B](#pone.0226452.g001){ref-type="fig"}.

### Short intra-cortical inhibition (SICI) {#sec017}

Results showed that IULF patients with NRS ≥4 statistically differed from healthy controls (*U* = 202.00; p\<0.01), with NRS ≥4 IULF patients exhibiting reduced short-intracortical inhibition of M1. A tendency toward reduced short-intracortical inhibition was found in IULF patients with NRS ≥4 compared to IULF patients with NRS \<4, but the difference failed to reach significance (*U* = 282.50; p = 0.08),. Lastly, IULF patients with NRS\<4 and healthy controls showed similar SICI (*U* = 383.00; p = 0.44). See [Fig 1C](#pone.0226452.g001){ref-type="fig"}. We then conducted a post-hoc linear regression to assess the contribution of both pain intensity and delay between the accident and testing on SICI disinhibition. Data shows that pain intensity at the time of testing significantly predicted SICI disinhibition and explained 29% of the variance (β-coefficient = 0.29; p = 0.05), whereas the delay between the accident and testing poorly predicted SICI disinhibition (β-coefficient = 0.07; 0.63).

### Intra-cortical facilitation (ICF) {#sec018}

IULF patients with NRS≥4 exhibited a significantly reduced ICF (t~(54)~ = 2.44; p = 0.02) relative to IULF patients with NRS\<4. IULF patients with NRS≥4 (t~(51)~ = -1.63; p = 0.11) and IULF with NRS\<4 (t~(57)~ = 0.37; p = 0.71) did not statistically differ from healthy controls. See [Fig 1D](#pone.0226452.g001){ref-type="fig"}. Results from a post-hoc linear regression showed that pain intensity significantly predicted altered ICF (β-coefficient = -0.30; p = 0.04), accounting for 30% of the variance, whereas delay between the accident and testing (β-coefficient = -0.02; p = 0.87) poorly predicted altered ICF.

### Long-interval cortical inhibition (LICI) {#sec019}

IULF patients with NRS≥4 had similar LICI values compared to IULF patients with NRS\<4 (*U* = 339.00; p = 0.42) and healthy controls (*U* = 324.00; p = 0.64). IULF patients with NRS\<4 and healthy controls were also equivalent on LICI (*U* = 405.00; p = 0.66). See [Fig 1E](#pone.0226452.g001){ref-type="fig"}.

Post-hoc analyses controlling for the side of the stimulated hemisphere in IULF patients {#sec020}
----------------------------------------------------------------------------------------

To investigate if the stimulated hemisphere had an impact on cortical excitability measures, IULF patients were stratified into two distinct groups: IULF patients stimulated on the left M1 and IULF patients stimulated on the right M1. Demographic data such as age (*U* = 296.00; p = 0.12), sex (X^2^~(1)~ = 0.002; p = 0.96), education level (t~(54)~ = 1.17; p = 0.25), and the timing of testing in relation to the accident (*U* = 339.50; p = 0.39) were similar across groups (see [Table 3](#pone.0226452.t003){ref-type="table"}). Lastly, there was no between-group difference in regard to pain intensity (*U* = 297.50; p = 0.12).

10.1371/journal.pone.0226452.t003

###### Descriptive characteristics of IULF patients according to the stimulated hemisphere.

![](pone.0226452.t003){#pone.0226452.t003g}

                                                                                     IULF subgroup Left M1   IULF subgroup Right M1   Results of the test analysis   p-value
  ---------------------------------------------------------------------------------- ----------------------- ------------------------ ------------------------------ ---------
  N ***(subjects)***                                                                 27                      29                                                      --
  Age ***(years \[SD\])***                                                           36.44 (12.40)           42.17 (13.18)            *U* = 296.00                   0.12
  Sex ***(female \[%\])***                                                           11 (41%)                12 (43%)                 X^2^ = 0.002                   0.96
  Education ***(years*** *\[****SD\])***                                             14.59 (3.06)            13.70 (2.51)             *t* = 1.17                     0.25
  Number of days between trauma and data collection/assessment ***(days \[SD\])***   5.67 (3.92)             6.66 (4.65)              *U* = 339.50                   0.39
  NRS Actual pain ***(SD)***                                                         2.81 (2.83)             3.59 (2.13)              *U* = 297.50                   0.12

### Group differences on M1-cortical excitability measures in relation to M1 stimulation side {#sec021}

None of the TMS measures differed across IULF patients according to the stimulated hemisphere \[rMT (*U* = 359.00; p = 0.93); SICI (*U* = 377.00; p = 0.81); ICF (t~(54)~ = -0.44; p = 0.6); LICI (*U* = 361.50; p = 0.62)\]. See [Fig 2A--2D](#pone.0226452.g002){ref-type="fig"}.

![Between IULF-group differences on TMS measures stratified according to the stimulated hemisphere.\
A. Between IULF-group differences on rMT stratified according to the stimulated hemisphere. B. Between IULF-group differences on SICI stratified according to the stimulated hemisphere. C. Between IULF-group differences on ICF stratified according to the stimulated hemisphere. D. Between IULF-group differences on LICI stratified according to the stimulated hemisphere.](pone.0226452.g002){#pone.0226452.g002}

### Relationship between cortical excitability measures and functional disability outcomes {#sec022}

The DASH questionnaire was used to investigate the relationship between functional disability outcomes and cortical excitability parameters. Only IULF subjects were included in this analysis, whereas healthy controls were excluded. Results show that the DASH score was strongly associated with SICI (R~s~ = 0.37; p = 0.006), whereas no correlation was found with ICF (r = -0.11; p = 0.46), LICI (R~s~ = -0.06; p = 0.67), and rMT (R~s~ = 0.18; p = 0.22).

Discussion {#sec023}
==========

This study provides new insights into the involvement of the primary motor cortex in the early phase of recovery (\<14 days post-trauma) following an IULF through various TMS protocols assessing M1-cortical excitability. More precisely, results suggest a significant decrease in intracortical inhibition and facilitation in IULF patients over the cortical representation of the fractured bone. These neurophysiological alterations were only observed in IULF patients with pain of moderate to severe intensity (NRS ≥4), whereas IULF patients with mild pain did not differ from healthy controls. Furthermore, this study highlights that the time elapsed between the accident and testing within the first 14 days of the accident, as well as the stimulated hemisphere, do not influence any of the primary motor cortex excitability measures. On the contrary, pain intensity emerges as the main factor explaining acute abnormalities of M1 excitability in IULF patients relative to a healthy cohort of similar age, sex distribution, and education level. To the best of our knowledge, this is the first study to investigate M1-cortical excitability in acute pain following an isolated upper limb fracture.

This study suggests a state of disinhibition through reduced SICI, a TMS measure that is robustly associated to GABA~A~ receptors activity \[[@pone.0226452.ref052]\], but only in patients with moderate to severe pain intensity (NRS ≥4). Moreover, the extent of SICI disruption was strongly associated with functional disability scores (DASH). Current findings highlight possible resemblance across pain states, as SICI disturbances are also found in various chronic pain conditions \[[@pone.0226452.ref007], [@pone.0226452.ref059]--[@pone.0226452.ref061]\]. A reduction of GABAergic inhibition has been shown to play a prominent role in chronic pain development and in pain maintenance \[[@pone.0226452.ref062]\]. It is therefore no surprise that GABA receptor agonists have proven effective as an analgesic agent, but important side effects limit its long-term use \[[@pone.0226452.ref063], [@pone.0226452.ref064]\]. Identification of a state of disinhibition at such an early stage of recovery in patients with a fracture is of particular clinical relevance in this population since high initial pain is considered a risk factor for chronic pain development \[[@pone.0226452.ref065]\]. These results may further our understanding as to why high levels of pain in the acute phase is considered a risk factor for chronic pain. Indeed, patients with moderate to severe pain (NRS ≥4) are affected by disrupted GABAergic inhibition within the first few days post-trauma, which may hypothetically contribute to CNS' vulnerability to pain chronification.

Of note, current findings diverge from results found in experimental acute pain studies. Experimentally induced pain in healthy controls shows an increase in M1 intracortical inhibition whereas the current study found a decrease in inhibition in IULF patients presenting with moderate to severe acute pain (NRS ≥4). Increased SICI in acute experimental pain has been suggested as an adaptation strategy to prevent CNS reorganization \[[@pone.0226452.ref032]\]. Given the reverse pattern of M1 disinhibition in IULF patients, one should investigate whether moderate to severe pain symptoms in the latter clinical population may facilitate lasting CNS reorganization through sustained activation of plasticity mechanisms. One reason for the discrepancies in SICI findings between experimental and acute clinical pain could be that fracture pain involves multiple physiological mechanisms that cannot be replicated in a human experimental setting. For example, the physiological cascade following tissue injury and bone fracture alone, including an acute inflammatory response, can modulate brain excitability \[[@pone.0226452.ref066]\] and impair GABAergic and glutamatergic activities \[[@pone.0226452.ref067]\]. Future studies combining both experimental paradigms in a healthy cohort and clinical pain in OT patients are warranted if we are to investigate the mechanisms involved and to restrict results discrepancy due to possible methodological variabilities.

Current results also reveal alterations of intracortical facilitation in IULF patients with moderate to severe pain (NRS ≥4), a measure traditionally considered to be mediated by glutamatergic facilitatory transmission \[[@pone.0226452.ref052]--[@pone.0226452.ref056]\]. The finding that both ICF and SICI are reduced may appear counterintuitive from a physiological standpoint. However, physiological underpinnings of TMS-induced ICF effects have been the subject of ongoing debate, as some evidence suggest that the latter reflects an overlap between inhibitory and excitatory mechanisms \[[@pone.0226452.ref054]\]. Along those lines, pharmacological studies have shown that both NMDA receptors antagonists (such as dextromethorphan and memantine) as well as GABA~A~ agonists can modulate ICF. In parallel, some TMS and chronic pain studies have shown reduced ICF, but this was mainly found in patients with fibromyalgia \[[@pone.0226452.ref011], [@pone.0226452.ref061]\]. Additional factors relevant to the orthopedic population could also account for current study findings. For example, other types of pain (muscle pain, bone pain, etc.) and inflammatory response can influence the balance between inhibitory and facilitatory mechanisms \[[@pone.0226452.ref066], [@pone.0226452.ref067]\]. Moreover, limb disuse may also affect brain plasticity due to reduced sensorimotor input and output \[[@pone.0226452.ref068]--[@pone.0226452.ref070]\].

Current findings support work from Pelletier and colleagues \[[@pone.0226452.ref029]\] suggesting that pain intensity, rather than pain state, appears to be linked to the extent of motor cortex excitability alterations. As such, patients who reported moderate to severe pain (NRS ≥4) showed accentuated SICI and ICF alterations as compared to patients with mild pain levels who showed a similar M1 excitability profile to healthy controls. This is particularly interesting as results from the current study showed that patients with higher pain levels also reported greater functional disability. Therefore, study findings are not only consistent with the notion that high initial pain is a good predictor for chronic pain, but it also argues that altered cortical excitability of M1 could contribute to underlying mechanisms of pain chronification following a fracture \[[@pone.0226452.ref071], [@pone.0226452.ref072]\].

Although a similar M1-cortical excitability profile may emerge between acute and chronic injury phases, the involvement of the CNS may be different. One should bear in mind that altered SICI and ICF in acute pain do not necessarily indicate permanent CNS reorganization. Although speculative, acute changes in M1-cortical excitability could also reflect the intensity of the nociceptive afferent originating from the periphery. It should be noted that the group of patients reporting moderate to severe (NRS ≥4) pain levels who also exhibited altered M1-cortical excitability were tested at a significantly shorter delay following the accident relative to patients who reported mild levels of pain. One cannot exclude the possibility that alterations of M1-cortical excitability within the first few days of the injury could have subsided as pain intensity is expected to reduce with additional time to recover. However, results from linear regressions, used to delimitate the weight of the timing of testing in relation to the accident and pain intensity on altered M1-cortical excitability, showed that pain intensity best predicted altered intracortical inhibition and facilitation, whereas timing of testing had no impact within that short 14-day time frame. Longitudinal follow-ups are nonetheless needed to investigate longitudinal changes of TMS-induced M1 excitability measurements in relation with pain stages, particularly during the transition from acute to chronic pain.

LICI, another measure reflecting GABA~B~ receptors inhibition, was found to be unrelated to reported pain intensity following a peripheral injury. In a recent review, authors only found scarce evidence of the involvement of LICI alterations in various chronic pain conditions \[[@pone.0226452.ref007]\], either suggesting that GABA~B~ receptors remain intact or that the latter measure may be less sensitive to pain states. It would still appear relevant to include other TMS paradigms known to measure GABA~A~ and GABA~B~ receptors, namely short-afferent inhibition (SAI), long-afferent inhibition (LAI), and the cortical silent period (CSP) in the context of future studies \[[@pone.0226452.ref054], [@pone.0226452.ref073]\]. This would allow us to deepen our understanding of the involvement of acute pain on the GABAergic inhibitory system in IULF patients.

Given the known durable effects of multisession rTMS protocols on M1-cortical excitability and on pain reduction, rTMS appears as a highly relevant intervention avenue for the IULF population. Acute rTMS application should be considered as an intervention option as it may provide analgesic effects to suffering patients, in addition to possibly tackling cortical excitability changes associated with pain chronification.

One limitation to the current study is the use of a single TMS session to investigate M1-cortical excitability implications in the acute phase of an IULF in relation to pain intensity. Longitudinal studies are needed among this population to further explore the effects of early M1-cortical excitability dysregulations on recovery. This would provide valuable insights as to whether acute altered M1-cortical excitability is a predictor of pain chronification. Secondly, this study uses limited, but well established, TMS parameters. Still, it should be considered that TMS parameters vary greatly across studies (e.g. ISI, test and conditioned stimuli intensity), surely contributing to result variability found in the literature. This poses a challenge for researchers to establish the most sensitive and specific TMS parameters. In the context of the present study, it should be considered that previous studies have highlighted possible contamination by short-interval cortical facilitation (SICF) in SICI according to the TMS parameters used \[[@pone.0226452.ref074], [@pone.0226452.ref075]\]. Although the present study uses parameters from previously published studies, SICF contamination cannot be excluded. It would be important to account for these findings in future studies. Moreover, the use of additional TMS paradigms (SAI, LAI, CSP) as well as an objective measure of pain, such as conditioned pain modulation \[[@pone.0226452.ref076], [@pone.0226452.ref077]\], would be highly relevant in the context of future studies to draw a thorough physiological profile of ascending and descending tracks in IULF patients with moderate to severe pain (NRS ≥4). Thirdly, since the initial medical consultations varied across IULF individuals, timing of testing post-accident was not equivalent within the IULF group. Although post-hoc analyses showed that this factor did not influence TMS outcomes, future studies should, to the extent possible, assess patients at a fixed day since the physiological cascade following the injury is rapidly evolving. Fourthly, pain medication usage and dosage at the time of testing were not restrained in IULF patients, possibly leading to interindividual variability among the sample. Effects of analgesics medication on cortical excitability measures cannot be excluded although very scarce evidence exists. One study showed that acetaminophen can increase MEP, which facilitates the inhibition of voltage-gated calcium and sodium currents \[[@pone.0226452.ref078]\]. In this case, and in relation with current study results showing decreased intracortical inhibition, acetaminophen usage among study sample could have masked cortical excitability deficiencies. As for opioid analgesics, only one study mentioned that fentanyl does not alter MEP amplitudes \[[@pone.0226452.ref056]\], a drug that is rarely used to treat acute pain. Fifthly, future studies should also account for additional factors, such as the inflammatory cascade (pro-inflammatory cytokines levels) and genetic predisposition, as they are known to impact pain intensity and M1-cortical excitability measures \[[@pone.0226452.ref079]--[@pone.0226452.ref082]\]. Accounting for such factors would be beneficial to develop tailored interventions for the IULF population. Sixthly, the stimulated hemisphere (right or left M1) varied in IULF patients according to the injured side. This factor was controlled for in IULF patients and no differences were found. On the other hand, all healthy controls were right-handed and were stimulated on the left-M1, which corresponds to the dominant hemisphere as per optimal TMS guidelines. Since no differences were found among the clinical sample, we elected to follow the TMS guidelines in the healthy sample. Finally, evidence show that reduced use of limb (limb immobilization) can indeed lead to brain changes (cortical thickness, cortical excitability, etc.) in the motor cortex due to reduced sensory input/sensorimotor deprivation \[[@pone.0226452.ref068]--[@pone.0226452.ref070], [@pone.0226452.ref083]\]. We can by no mean exclude this factor entirely, but a few points should be considered. First, IULF patients were tested very early post-injury, leaving less time for measurable brain changes. Second, statistical analyses show that the number of days between testing and the accident (possible indicator of reduced limb use) is not associated with alterations in cortical excitability measures. Lastly, IULF patients who showed most cortical excitability deficiencies were actually tested within shorter delays of accident (NRS \>4 group), leaving less time, compared to the other IULF group (NRS\<4), for cortical reorganization due to limb immobilization.

Conclusions {#sec024}
===========

In conclusion, this is the first study to investigate M1 cortical excitability involvement in an orthopedic trauma population suffering from acute pain. Current results show early signs of altered GABAergic inhibitory and glutamatergic facilitatory activities in patients with pain of moderate to severe intensity (NRS ≥4). These findings may bear major clinical significance as this population is vulnerable to chronic pain development. Early detection of at-risk patients could guide proactive intervention aiming to reduce the likelihood of an unsuccessful recovery in this population, leading to a pathological condition. This study also highlights that acute application of rTMS may reveal promising in alleviating pain symptoms among this population and may have implications in preventing chronic pain development.
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Dear Dr De Beaumont,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

As you will see below, the two Reviewers have expressed several concerns regarding the methodological approach. In particular, the Reviewers were concerned by the validity of the comparison between groups and possible interactions with drugs. Also, the Reviewers point to potential issues with the way the statistical analysis was carried out, notably for post-hoc comparisons. Finally, Reviewer 1 has several suggestions to improve the overall quality of the manuscript.  Please make sure that all significant issues and concerns are adequately addressed in the revised version. 

We would appreciate receiving your revised manuscript by Feb 10 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

François Tremblay, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The study by Jodoin and colleagues used single- and paired-pulse transcranial magnetic stimulation (TMS) to investigate changes in motor cortical excitability following isolated upper limb fracture. Several measures of intracortical function were applied in the acute injury phase, with the patient population stratified in to two groups based on reporting either mild or moderate-severe levels of injury-related pain. Relative to a healthy control group, the authors report that only measures of SICI were altered in patients with moderate-severe levels of pain. This change was interpreted as a specific effect of injury on GABAA-mediated circuits in primary motor cortex. Some specific comments about this study are listed below:

Major

1\. The introduction is very long, including a lot of detail that could perhaps be left to the discussion. Please adopt a more concise approach.

2\. The authors state that standard exclusion criteria were used for TMS, but I can't see any mention of exclusion due to drugs; were participants excluded due to prescription drug use? Also, it seems likely that patients would have been using some kind of pain management during this early period -- was this the case? If so, how could this have influenced the study findings?

3\. I appreciate the effort that the authors have made to demonstrate that the mixed handedness of the patient group is not of importance. However, it seems like this issue could have been overcome by matching handedness between patients and controls. Why was this not done?

4\. A conditioning intensity of 0.8RMT was used for SICI, with an ISI of 3 ms. As this conditioning intensity approximates 100%AMT (Garry et al., 2009), it's possible that measures of SICI were contaminated by SICF (i.e., Peurala et al., 2008). This point should be addressed.

5\. The authors make no comment about the normality of their data. Was this assessed? Were measures taken to adjust for non-normal data?

6\. Several of the ANOVAs failed to indicate an effect of group, yet post hoc comparisons were still performed between groups (i.e., measures of RMT, ICF and LICI). This is not appropriate, and these comparisons should be removed from the manuscript.

7\. It doesn't appear that the authors included any corrections for multiple comparisons in their post hoc tests. Please include an appropriate measure where necessary.

8\. Please report information about the response to test alone stimulation. Where the MEPs comparable between groups?

9\. Individual panels of the same figure should be grouped together as s single image. In addition, as the post hoc statistics are reported in the text, it is not necessary to repeat them in each panel; please remove these from all figures.

10\. At several points in the manuscript, the authors refer to 'clinically significant' pain. Can they provide some information and references on how they define pain as clinically significant?

11\. LICI is expressed as a ratio, whereas all other paired-pulse measures are expressed as a percentage; why the difference between measures?

12\. Did the authors investigate relationships between neurophysiological measures and outcomes of the DASH? This analysis would be of interest and should be reported.

13\. The authors state that changes in intracortical inhibition may reflect plasticity processes as a direct response to injury. However, can they provide any evidence to show that changes in use of the limb (i.e., a secondary effect of injury) weren't responsible for the observed neurophysiological changes?

14\. It is unclear how the neurophysiological alterations observe in the acute phase support high initial pain as a predictor for chronic pain, or how the reported results demonstrate that changes in M1 lead to pain chronification (lines 422-425)? Can the authors please clarify how they reached this conclusion based on the empirical information they report?

15\. I agree that these findings may indicate the investigation of rTMS for normalising neurophysiological changes in acute pain. However, the authors statement that this approach is 'particularly promising' (line 455) for 'providing analgesic effects' (line 455) is probably overzealous. Please tone down these kinds of comments.

Minor

1\. Please reword the methods section of the abstract for clarity.

2\. Line 136, Typo -- Wee

3\. Line 206 -- please clarify the use of the term 'vertex' in this context. Are the authors suggesting that stimulation was applied to the vertex?

4\. Line 213 -- please clarify RMT criteria; the standard approach recommended by the most recent IFCN guidelines is a 0.05 mV MEP in at least 5/10 stimuli. The authors erroneously state that 0.5 mV in 6/10 stimuli.

5\. Line 408 -- please correct spelling of dextromethorphan

6\. Line 449-450 - please provide refs for statements that SAI and LAI reflect GABAA and GABAB mediated neurotransmission, respectively.

Reviewer \#2: PONE-D-19-32702: Clinically significant acute pain disturbs motor cortex intracortical inhibition and facilitation in orthopedic trauma patients: A TMS study

In the present study, the authors investigated M1 area excitability in patients with acute pain due to isolated upper limb fracture. It is shown that SICI and ICF are reduced in patients with moderate to severe pain, while they were similar to those of healthy controls in patients with mild pain. The authors suggest that the present results may represent a conceptual background for the therapeutic use of TMS in acute pain.

The study is well conducted and the results are discussed correctly.

I have some points:

1\) How can the authors exclude that the abnormal M1 excitability is due to the lower use of the painful upper limb? Patients with higher pain are supposed to use their painful upper limb less than those with lower pain and control subjects. Immobilization is known to lead to M1 excitability changes (Viaro et al., J Physiol 2014).

2\) As for the effect on ICF, ANOVA was not significant. Are the authors allowed to perform post-hoc analysis?

3\) Could the authors exclude any pharmacological effect? In other words, was the last assumption of analgesic drugs before the neurophysiological investigation checked?

4\) In the Introduction, the pioneering papers by Valeriani et al. (Clin Neurophysiol 1999, Exp Brain Res 2001) on the M1 area inhibition after experimental phasic pain should be quoted.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Massimiliano Valeriani

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

7 Feb 2020

Major

Question \#1: The introduction is very long, including a lot of detail that could perhaps be left to the discussion. Please adopt a more concise approach.

Response to question \#1: Thank you for your comment. We have made an effort to be more concise.

Question \#2: The authors state that standard exclusion criteria were used for TMS, but I can't see any mention of exclusion due to drugs; were participants excluded due to prescription drug use? Also, it seems likely that patients would have been using some kind of pain management during this early period -- was this the case? If so, how could this have influenced the study findings?

Response to question \#2: This is a very good point. We have actually controlled for drug consumption by excluding individuals consuming specific types of drugs at the time of recruitment or within a period of six months prior to recruitment. This was added to the manuscript. Patients with fractures were not restrained from taking pain-related medication at the time of testing to assure comfort and to limit interference with pain management. Very few TMS studies have focused on assessing the impact of pain-related medication on cortical excitability measures. One study showed that acetaminophen consumption, pain-related medication typically recommended to reduce pain following a mild fracture, can interact with cortical excitability measures, specifically by increasing motor evoked potential (MEP; Mauger et al., 2013). This increase in MEP was found to facilitate the inhibition of voltage-gated calcium and sodium currents (Mauger et al., 2013). In this case, and in relation with current study results showing decreased intracortical inhibition, acetaminophen usage among study sample could have masked cortical excitability deficiencies. It appears that acetaminophen does not impact other cortical excitability measures. As for opioid analgesics, one study mentioned that fentanyl does not alter MEP amplitude (<https://www.sciencedirect.com/science/article/pii/S1388245704001038>). Fentanyl is rarely used to treat acute pain. Otherwise, there is no clear evidence to support that opioids will impact cortical excitability measures. This factor was added to the limitation section.

3\. I appreciate the effort that the authors have made to demonstrate that the mixed handedness of the patient group is not of importance. However, it seems like this issue could have been overcome by matching handedness between patients and controls. Why was this not done?

Response to question \#3: Handedness in TMS studies is often controlled for due to cortical organization by recruiting only right-handed subjects. In order to reduce variability in healthy controls, we opted to apply strict inclusion criteria by excluding left-handed subjects. Moreover, since no difference was found in the clinical group according to stimulation site, we did not judge essential to match with healthy controls based on that criteria.

4\. A conditioning intensity of 0.8RMT was used for SICI, with an ISI of 3 ms. As this conditioning intensity approximates 100%AMT (Garry et al., 2009), it's possible that measures of SICI were contaminated by SICF (i.e., Peurala et al., 2008). This point should be addressed.

Response to question \#4:

Although we are aware of the possibility of measure contamination, we were concerned with being consistent with the overwhelming use of these stimulation parameters for SICI measurement among existing TMS and pain studies.

More importantly, although using AMT would make sense theoretically, we do not think it is as fitting in the context of the current study considering the particularities of the studied population. Participants from the orthopedic trauma group are assessed within a few days post-injury which resulted in a fracture of an upper limb. Requiring multiple slight muscle contractions of the hand could potentially inflict inter-subject variability depending on fractured bones, and may also induce pain, especially since it involves contracting the muscle of the affected side. We feel that it could have added another confounding variable. Moreover, a 2012 study assessed the reliability of TMS measures under both resting and active conditions. 3ms-SICI under AMT and RMT conditions were both considered reliable (Ngomo et al., 2012) and for reproducibility, SICI measured at rest was deemed preferable.

5\. The authors make no comment about the normality of their data. Was this assessed? Were measures taken to adjust for non-normal data?

Response to question \#5: Thanks for picking that up. We checked for data normality and results obtained required the use of non-parametric statistics analyses in most measures. We have made the necessary changes in the manuscript.

6\. Several of the ANOVAs failed to indicate an effect of group, yet post hoc comparisons were still performed between groups (i.e., measures of RMT, ICF and LICI). This is not appropriate, and these comparisons should be removed from the manuscript.

Response to question \#6: We have removed post hoc analyses when uncalled for. We have also elected to use an approach by pairing groups (t-test and Mann-Whitney U test), instead of regrouping all three groups together, since the primary hypothesis of the current study is that patients with higher levels of pain show more disturbed M1-cortical excitability measures.

7\. It doesn't appear that the authors included any corrections for multiple comparisons in their post hoc tests. Please include an appropriate measure where necessary.

Response to question \#7: We have now controlled for multiple comparisons and made the necessary corrections.

8\. Please report information about the response to test alone stimulation. Were the MEPs comparable between groups?

Response to comment \#8: We have conducted a Mann-Whitney U (SICI) test and t-test (ICF) to compare MEPs of the test stimulus between groups. Results show that test stimulus MEPs are comparable between groups.

9\. Individual panels of the same figure should be grouped together as a single image. In addition, as the post hoc statistics are reported in the text, it is not necessary to repeat them in each panel; please remove these from all figures.

Response to comment \#9: We have proceeded to combine figures.

10\. At several points in the manuscript, the authors refer to 'clinically significant' pain. Can they provide some information and references on how they define pain as clinically significant?

Response to comment \#10: We have removed this terminology and replaced it with "moderate to severe pain" (NRS �4).

11\. LICI is expressed as a ratio, whereas all other paired-pulse measures are expressed as a percentage; why the difference between measures?

Response to comment \#11: We have transformed the scores to obtain percentage ratios as opposed to ratio. All TMS scores are presented as percentage ratios.

12\. Did the authors investigate relationships between neurophysiological measures and outcomes of the DASH? This analysis would be of interest and should be reported.

Response to comment \#12: we have conducted additional analyses to explore the association between DASH and TMS measures. A new section was added in the article.

13\. The authors state that changes in intracortical inhibition may reflect plasticity processes as a direct response to injury. However, can they provide any evidence to show that changes in use of the limb (i.e., a secondary effect of injury) weren't responsible for the observed neurophysiological changes?

Response to question \#13: Evidence show that reduced use of limb (limb immobilization) can indeed lead to brain changes (cortical thickness, cortical excitability, etc.) in the motor cortex due to reduced sensory input/sensorimotor deprivation. We can by no mean exclude this factor entirely, but a few points should be considered. First, IULF patients were tested very early post-injury, leaving less time for measurable brain changes. Second, statistical analysis show that the number of days between testing and the accident (possible indicator of reduced limb use) is not associated with alterations in cortical excitability measures. Lastly, IULF patients who showed most cortical excitability deficiencies were actually tested within shorter delays of accident (NRS \>4 group), leaving, again, less time, compared to the other IULF group (NRS\<4), for cortical reorganization due to limb immobilization.

14\. It is unclear how the neurophysiological alterations observe in the acute phase support high initial pain as a predictor for chronic pain, or how the reported results demonstrate that changes in M1 lead to pain chronification (lines 422-425)? Can the authors please clarify how they reached this conclusion based on the empirical information they report?

Response to comment \#14: We have rephrased the information. In the absence of longitudinal studies, we agree that this assumption cannot be made with confidence.

15\. I agree that these findings may indicate the investigation of rTMS for normalising neurophysiological changes in acute pain. However, the authors statement that this approach is 'particularly promising' (line 455) for 'providing analgesic effects' (line 455) is probably overzealous. Please tone down these kinds of comments.

Response to comment \#15: We have applied the suggested changes.

Minor

1\. Please reword the methods section of the abstract for clarity.

We have made some corrections to improve clarity.

2\. Line 136, Typo -- Wee

Correction was made.

3\. Line 206 -- please clarify the use of the term 'vertex' in this context. Are the authors suggesting that stimulation was applied to the vertex?

We have used a different terminology.

4\. Line 213 -- please clarify RMT criteria; the standard approach recommended by the most recent IFCN guidelines is a 0.05 mV MEP in at least 5/10 stimuli. The authors erroneously state that 0.5 mV in 6/10 stimuli.

We have corrected this mistake, we actually cited the IFCN but wrongly put 6/10 instead of 5/10, as it is stated in the article.

5\. Line 408 -- please correct spelling of dextromethorphan

We have corrected this typo.

6\. Line 449-450 - please provide refs for statements that SAI and LAI reflect GABAA and GABAB mediated neurotransmission, respectively.

We have added references. With further research, we found that LAI is not a direct measure of GABAB mediated neurotransmission, although previous studies have made that statement (1). We still believe that LAI should be used in future studies, therefore decided to still mention LAI in the current study.

Reviewer \#2: PONE-D-19-32702: Clinically significant acute pain disturbs motor cortex intracortical inhibition and facilitation in orthopedic trauma patients: A TMS study

In the present study, the authors investigated M1 area excitability in patients with acute pain due to isolated upper limb fracture. It is shown that SICI and ICF are reduced in patients with moderate to severe pain, while they were similar to those of healthy controls in patients with mild pain. The authors suggest that the present results may represent a conceptual background for the therapeutic use of TMS in acute pain.

The study is well conducted and the results are discussed correctly.

I have some points:

1\) How can the authors exclude that the abnormal M1 excitability is due to the lower use of the painful upper limb? Patients with higher pain are supposed to use their painful upper limb less than those with lower pain and control subjects. Immobilization is known to lead to M1 excitability changes (Viaro et al., J Physiol 2014).

Response to question \#1: See response to question \#13 from Reviewer \#1.

2\) As for the effect on ICF, ANOVA was not significant. Are the authors allowed to perform post-hoc analysis?

Response to question \#2: We have removed post hoc analyses when uncalled for.

3\) Could the authors exclude any pharmacological effect? In other words, was the last assumption of analgesic drugs before the neurophysiological investigation checked?

Response to question \#3: See response to question \#2 from Reviewer \#1. We have added a comment in this regard in the limit section.

4\) In the Introduction, the pioneering papers by Valeriani et al. (Clin Neurophysiol 1999, Exp Brain Res 2001) on the M1 area inhibition after experimental phasic pain should be quoted.

Response to question \#4: Thank you for this relevant suggestion. We have added both citations in the introduction.
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Moderate to severe acute pain disturbs motor cortex intracortical inhibition and facilitation in orthopedic trauma patients: A TMS study

PLOS ONE

Dear Dr De Beaumont,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your revised manuscript was received favourably by the Reviewers. While Reviewer \#1 was mostly satisfied, there are few remaining minor issues for you to address (e.g., interpretation of modulation in SICI). I am sure that you can address these issues promptly and hope to get a revised version shortly.

We would appreciate receiving your revised manuscript by Apr 11 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

François Tremblay, PhD

Academic Editor

PLOS ONE rega
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: While the authors have addressed most of my concerns, a few issues remain:

1\. In regards to contamination of SICI by SICF, I was not suggesting to use AMT. The issue could have been accounted for by using a lower %RMT conditioning stimulus. I understand why the authors would want to include the intensity commonly tested within the existing literature, but inclusion of an additional, lower intensity, conditioning stimulus would have been very feasible. At the very least, the possibility of SICF contamination should be addressed to some degree in the discussion.

2\. The authors did not address why they elected to retain outcomes of all post-hoc comparisons in the figures, despite the fact that they're reported in the text (see comment 9).

3\. Typos on line 224 (RMT criteria still refer to 0.5mV MEP, which should be 0.05mv) and 243 (LICI stimuli referred to as subthreshold, should be suprathreshold).

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Massimiliano Valeriani

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Comment \#1: In regard to contamination of SICI by SICF, I was not suggesting to use AMT. The issue could have been accounted for by using a lower %RMT conditioning stimulus. I understand why the authors would want to include the intensity commonly tested within the existing literature, but inclusion of an additional, lower intensity, conditioning stimulus would have been very feasible. At the very least, the possibility of SICF contamination should be addressed to some degree in the discussion.

Response to Comment \#1: We have addressed this comment in the limitation section.

Comment \#2: The authors did not address why they elected to retain outcomes of all post-hoc comparisons in the figures, despite the fact that they're reported in the text (see comment 9).

Response to Comment \#2: Our apologies. We have made the necessary changes and removed all results from the post-hoc statistics.

Comment \#3: Typos on line 224 (RMT criteria still refer to 0.5mV MEP, which should be 0.05mv) and 243 (LICI stimuli referred to as subthreshold, should be suprathreshold).

Response to comment \#3: Thank you for picking that up. We have made the necessary changes.
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Click here for additional data file.
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Dear Dr. De Beaumont,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

François Tremblay, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Just one minor typo in the new text addressing SICF - you\'ve listed short afferent cortical facilitation, which should be short interval.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: George Opie
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Moderate to severe acute pain disturbs motor cortex intracortical inhibition and facilitation in orthopedic trauma patients: A TMS study

Dear Dr. De Beaumont:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. François Tremblay

Academic Editor

PLOS ONE
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